BCTX BriaCell Therapeutics Corp.: רווח נקי למניה ב-12 החודשים האחרונים

BriaCell Therapeutics (BCTX) management is scaling clinical trials, which is temporarily increasing current expenditures. The trailing twelve months (ttm) net income per share growth rate visualizes the results of this strategy, where 87.70 shows the value of this parameter. Oncology experts ensure process transparency for investors, while innovative developments in the US and Canada create a foundation for the fight against breast cancer.
BCTX (BriaCell Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

When constructing a long-term portfolio, asset screening requires an analysis of earnings resilience amid liquidity contraction and high Fed rates. This indicator measures the percentage change in net income per share over the last twelve months, reflecting the efficiency of BriaCell Therapeutics (BCTX) in capitalizing on innovations in personalized cancer immunotherapy via the annual EPS TTM delta.